We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Steroids, hyaluronic acid injections, and regenerative therapies, such as PRP and stem cell injections, are among the ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

We recently published a list of 10 Most Promising Low-Cost Stocks According to Hedge Funds. In this article, we are going to ...

When Sanofi announced last week that it plans to sell a 50% controlling stake of Opella, its consumer helath business, the ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

Dr. Steven-Huy Han, a UCLA liver specialist, has prescribed Ocaliva to a handful of patients, although he’s not sure it helps ...

We recently compiled a list of the 10 Most Undervalued Quality Stocks To Buy According To Analysts. In this article, we will ...